UBS Group
DMAQR

UBS Group’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

UBS Group’s Portfolio DMAQR Stock Details DMAQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-400
Closed -$56 – 10199
2023
Q2 		$56 Buy
+400
New +$65 ﹤0.01% 8591
2023
Q1 		– Sell
-2
Closed – – 10900
2022
Q4 		$0 Buy
+2
New – ﹤0.01% 11387
2022
Q3 		– Sell
-2,998
Closed – – 11256
2022
Q2 		$0 Hold
2,998
– – ﹤0.01% 11260
2022
Q1 		$1K Buy
2,998
+700
+30% +$177 ﹤0.01% 10005
2021
Q4 		$1K Buy
+2,298
New +$727 ﹤0.01% 10088

Other funds holding DMAQR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

UBS Group's DMAQR Position: Q3 2023 in Review

UBS Group sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q3 2023, closing a stake of 400 shares — an estimated $56 sold.

UBS Group first reported a position in DMAQR in Q4 2021 and held it in 5 quarters. The position peaked at $1K in Q1 2022. 26 funds tracked by Wall St. Rank hold DMAQR as of Q3 2023.

  • UBS Group reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 400 Deep Medicine Acquisition Corp. Rights shares in Q3 2023, an estimated $56.
  • UBS Group first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 5 quarters.
  • UBS Group's Deep Medicine Acquisition Corp. Rights position peaked at $1K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.